| Pharmaceutical Information |
| Drug Name |
Alemtuzumab |
| Drug ID |
BADD_D00064 |
| Description |
Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. |
| Indications and Usage |
Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA34 |
| DrugBank ID |
DB00087
|
| KEGG ID |
D02802
|
| MeSH ID |
D000074323
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D01ZYG
|
| NDC Product Code |
58468-0200; 58468-0357 |
| UNII |
3A189DH42V
|
| Synonyms |
Alemtuzumab | Campath 1H | Monoclonal Antibody Campath-1H | Antibody Campath-1H, Monoclonal | Campath-1H, Monoclonal Antibody | Monoclonal Antibody Campath 1H | Campath-1H | Campath1H | Campath 1M | Campath-1M | MabCambath | Lemtrada | Campath 1G | Campath-1-G | Campath 1 G | Campath1G | Campath-1G | Campath |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
216503-57-0 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
